AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
BörsenkürzelRCEL
Name des UnternehmensAVITA Medical Inc
IPO-datumMar 18, 2012
CEOMr. James M. (Jim) Corbett
Anzahl der mitarbeiter260
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse28159 Avenue Stanford
StadtVALENCIA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl91355
Telefon16613679170
Websitehttps://www.avitamedical.com/
BörsenkürzelRCEL
IPO-datumMar 18, 2012
CEOMr. James M. (Jim) Corbett
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten